Sialic acid in sickle cell disease

Area of Science:

• Biochemistry
• Hematology
• Cell Biology

Background:

• Sickle cell disease (HbSS) is characterized by abnormal hemoglobin leading to erythrocyte damage.
• Erythrocyte surface glycoproteins, including sialic acid, are crucial for cell function and integrity.
• Previous research suggests potential alterations in erythrocyte membrane components in HbSS.

Purpose of the Study:

• To quantify serum neuraminic (sialic) acid concentrations in normal and HbSS individuals across different age groups.
• To investigate the impact of exogenous sialic acid on the reversion rate of sickled HbSS erythrocytes.
• To explore the role of erythrocyte sialic acid in the pathophysiology and recovery from sickling crises in HbSS.

Main Methods:

• Serum sialic acid levels were measured in pediatric and adolescent normal and HbSS subjects.
• In vitro experiments assessed the effect of varying concentrations of exogenous sialic acid on HbSS erythrocyte morphology.
• Sialidase treatment was used to partially remove sialic acid from HbSS erythrocytes, followed by deoxygenation and treatment with phenylalanine.

Main Results:

• Serum sialic acid concentrations were consistently lower in HbSS subjects compared to normal controls throughout childhood and adolescence.
• Exogenous sialic acid demonstrated a concentration-dependent ability to revert pre-sickled HbSS erythrocytes to normal morphology.
• Partial de-sialation of HbSS erythrocytes accelerated sickling upon deoxygenation and slowed recovery with phenylalanine treatment.

Conclusions:

• Reduced erythrocyte sialic acid content may be a significant factor in the accelerated sickling observed in sickle cell disease.
• Sialic acid plays a crucial role in modulating the rate of recovery from sickling crises in HbSS patients.
• Therapeutic strategies involving sialic acid supplementation could potentially aid in managing sickle cell disease progression and symptoms.